The phase 3 trial demonstrated significant improvements in overall and progression-free survival, reinforcing the combination as a standard-of-care option across MMR subgroups.
Vicky Makker, MD
Advertisement
Articles by Vicky Makker, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
3
FDA Approves Gazyva for Active Lupus Nephritis
4
Turning the Tide in TNBC: Trop2-Targeted Therapies Improve Patient Outcomes
5
